Use the hyperlinks, where available to access additional clinical trial information.
An Open-Label, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
This study has two stages: Dose Escalation and Dose Expansion. In the Dose Escalation stage, participants will receive RO7443904 and glofitamab will take place every three weeks (Q3W) with obinutuzumab pre-treatment. RO7443904 will be administered by subcutaneous injection or intravenous infusion on Cycle 2, Day 8. From Cycle 3 onward, RO7443904 will be given every 3 weeks, for up to 12 cycles. Glofitamab will be administered through IV infusion starting with step-up dosing (2.5 mg/10 mg/30 mg) on C1D1, C1D8, and C2D1. Starting in Cycle 3, glofitamab will be given in 30 mg doses every three weeks with RO7443904, for up to 12 cycles. Obinutuzumab will be administered once through IV infusion, at a 1 g dose in Cycle 1, on either Day -7, -4, or -3 (C1D-7, C1D-4, C1D-3). In the Dose Expansion phase, the selected dose levels of RO7443904 in combination with glofitamab from the Dose Expansion Phase in a Q3W regimen with obinutuzumab pre-treatment.